The survival analysis was performed on HCC patients treated with HAIC with FOLFOX...The progression-free survival (PFS) of DDR mutation group were significantly longer than wild-type group (median PFS, mutation vs. wild-type = 8.9 vs. 4.5 months; HR 0.34[95% CI 0.13-0.85]; P = 0.0349)....better treatment outcomes of HAIC with FOLFOX in DDR mutation HCC patients.